Sildenafil
- Generic Name
- Sildenafil
- Brand Names
- Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O4S
- CAS Number
- 139755-83-2
- Unique Ingredient Identifier
- 3M7OB98Y7H
- Background
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...
- Indication
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:
(1) the treatment of erectile dysfunction ; and
(2) treatment of pulmonary hypertension, where:
...
- Associated Conditions
- Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 56
- Registration Number
- NCT00644956
- Locations
- 🇬🇧
Pfizer Investigational Site, Leeds, United Kingdom
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 300
- Registration Number
- NCT00644631
- Locations
- 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States
A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 300
- Registration Number
- NCT00645268
- Locations
- 🇨🇦
Pfizer Investigational Site, Calgary, Canada
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 275
- Registration Number
- NCT00644605
- Locations
- 🇬🇧
Pfizer Investigational Site, HIGH Heaton, Newcastle-upon-tyne, United Kingdom
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
- Conditions
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT00625079
- Locations
- 🇺🇸
David Geffen School of Medicine UCLA, Los Angeles, California, United States
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 38
- Registration Number
- NCT00617305
- Locations
- 🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Sildenafil and Exercise Capacity in Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 30
- Registration Number
- NCT00599235
- Locations
- 🇬🇧
University of Edinburgh - Western General Hospital, Edinburgh, United Kingdom
Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
- Conditions
- Interventions
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Competence Network for Congenital Heart Defects
- Target Recruit Count
- 24
- Registration Number
- NCT00586794
- Locations
- 🇩🇪
Klinikum der Universität Heidelberg, Pädiatrische Kardiologie, Heidelberg, Baden-Wuertemberg, Germany
🇩🇪Universitätsklinikum Charite, Campus Virchow-Klinikum, Otto-Heubner-Centrum für Kinder- und Jugendmedizin, Berlin, Germany
🇩🇪Deutsches Herzzentrum München, Munich, Bavaria, Germany
Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 386
- Registration Number
- NCT00547092
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, United Kingdom
Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2760
- Registration Number
- NCT00547287
- Locations
- 🇧🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.